ABSTRACT This study aimed to evaluate associations among final weight (FW), average daily gain (ADG), scrotal circumference (SC), and visual score (VS) of beef cattle in performance tests on pasture or in feedlots. Genetic parameters for FW, ADG, SC, and VS of young Nellore bulls performance-tested on pasture or in feedlots were evaluated by mixed model. The performance test and final age were considered as fixed effects and additive genetic and residual effects were considered as random effects. Additive genetic and residual variances for final weight and average daily gain were smaller on pasture than in feedlots. There was no difference between genetic and residual variances and heritability for scrotal circumference on pasture or in feedlots. Genetic variance and heritability for visual score on pasture were smaller than those in feedlots. The posterior means (and highest posterior density intervals with 90% of samples (HPD90) in parentheses) for heritability were 0.46 (0.42; 0.50) and 0.49 (0.41; 0.55) for FW, 0.25 (0.22; 0.29) and 0.25 (0.19; 0.30) for ADG, 0.56 (0.51; 0.61) and 0.60 (0.51; 0.68) for SC, and 0.31 (0.27; 0.34) and 0.42 (0.36; 0.48) for VS on pasture or in feedlots, respectively. The genetic correlations (posterior means with HPD90 in parentheses) were 0.74 (0.69; 0.79) and 0.67 (0.58; 0.77) between FW and ADG; 0.49 (0.43; 0.55) and 0.60 (0.53; 0.68) for FW and SC; 0.79 (0.75; 0.83) and 0.85 (0.80; 0.90) for FW and VS; 0.37 (0.29; 0.46) and 0.34 (0.19; 0.50) for ADG and SC; 0.65 (0.59; 0.71) and 0.74 (0.64; 0.84) for ADG and VS; and 0.46 (0.39; 0.52) and 0.53 (0.44; 0.62) for SC and VS, obtained on pasture or in feedlots, respectively. The genetic and residual (co)variances of growth, scrotal circumference, and visual score of beef cattle vary across environments; however, genetic and residual correlation and efficiency of correlated response among these traits remain constant on pasture or in feedlots.

Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to 2% of the world's population. Immunobiological medications are prescribed for certain patients with severe forms of psoriasis, however, these drugs increase the risk of reactivation of viral diseases such as hepatitis B. We report the case of a patient with severe psoriasis with positive serology for the Hepatitis B virus, who received ustekinumab (a human monoclonal antibody against interleukin 12 and 23). In this patient, the use of ustekinumab did not reactivate the Hepatitis B virus. Given the high prevalence of chronic viral infections in patients who are candidates for biologic therapy, as well as the potential for reactivate chronic viral illness, randomized controlled studies are needed to assess the risks and benefits of such therapy in these populations.